Amneal Pharmaceuticals, Inc. (AMRX)

6,76 +0,55 (+8,86%) Alla chiusura: 04:00PM EDT

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://amneal.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 7.850

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Chirag K. Patel	Co-Founder, Co-CEO, President & Director	1,71M	N/D	1967
Mr. Chintu Patel R.Ph.	Co-Founder, Co-CEO & Director	1,7M	N/D	1972
Mr. Anastasios G. Konidaris	Executive VP & CFO	1,04M	N/D	1967
Mr. Jason B. Daly Esq.	Senior VP, Chief Legal Officer & Corporate Secretary	779,06k	N/D	1974
Ms. Nikita Shah	Executive VP & Chief Human Resources Officer	848,83k	N/D	1979
Mr. Andrew S. Boyer	Executive VP & Chief Commercial Officer of Generics	1,2M	N/D	1966
Mr. Anthony DiMeo	Head of Investor Relations	N/D	N/D	N/D
Mr. Gregory Sgammato	Senior Vice President of Corporate Development	N/D	N/D	N/D
Mr. Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	N/D	N/D	N/D
Dr. Sanjay Kumar Jain Ph.D.	Chief Quality Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Amneal Pharmaceuticals, Inc. al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 4; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.